Besifloxacin
- Generic Name
- Besifloxacin
- Brand Names
- Besivance
- Drug Type
- Small Molecule
- Chemical Formula
- C19H21ClFN3O3
- CAS Number
- 141388-76-3
- Unique Ingredient Identifier
- BFE2NBZ7NX
- Background
Besifloxacin is a fourth generation fluoroquinolone-type opthalmic antibiotic for the treatment of bacterial conjunctivitis. FDA approved on May 28, 2009.
- Indication
Treatment of bacterial conjunctivitis. Bacterial isolates that are susceptible to besifloxacin include: CDC coryneform group G; Corynebacterium pseudodiphtheriticum; Corynebacterium striatum; Haemophilus influenzae; Moraxella lacunata; Staphylococcus aureus; Staphylococcus epidermidis; Staphylococcus hominis; Staphylococcus lugdunensis; Streptococcus mitis group; Streptococcus oralis; Streptococcus pneumoniae; Streptococcus salivarius*
- Associated Conditions
- Bacterial Conjunctivitis
Corneal Endothelial Cell Density Changes In Healthy Subjects, When Administered ISV-403 for 5 Days
- First Posted Date
- 2010-05-11
- Last Posted Date
- 2012-08-13
- Lead Sponsor
- Bausch & Lomb Incorporated
- Target Recruit Count
- 120
- Registration Number
- NCT01120418
- Locations
- 🇺🇸
Bausch & Lomb, Rochester, New York, United States
Efficacy of Besifloxacin Ophthalmic Suspension in the Treatment of Bacterial Conjunctivitis
- Conditions
- Bacterial Conjunctivitis
- Interventions
- Drug: Vehicle (Placebo)
- First Posted Date
- 2009-09-09
- Last Posted Date
- 2012-03-29
- Lead Sponsor
- Bausch & Lomb Incorporated
- Target Recruit Count
- 474
- Registration Number
- NCT00972777
- Locations
- 🇺🇸
Bausch & Lomb Incorporated, Rochester, New York, United States
Study of Ocular Penetration of Topically Administered Fluoroquinolones
- Conditions
- Cataract Extraction
- Interventions
- First Posted Date
- 2009-06-19
- Last Posted Date
- 2017-10-24
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 50
- Registration Number
- NCT00924729
- Locations
- 🇺🇸
The Wilmer Eye Institute at Johns Hopkins University, Baltimore, Maryland, United States
Concentration of Besifloxacin, Gatifloxacin, and Moxifloxacin in Human Conjunctiva After Topical Instillation
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2009-05-21
- Last Posted Date
- 2011-12-09
- Lead Sponsor
- Bausch & Lomb Incorporated
- Target Recruit Count
- 119
- Registration Number
- NCT00905762
- Locations
- 🇺🇸
Bausch & Lomb Incorporated, Rochester, New York, United States
Assessment of the Concentrations of Besifloxacin, Moxifloxacin, or Gatifloxacin in the Aqueous Humor of Subjects
- Conditions
- Cataract Extraction
- Interventions
- First Posted Date
- 2009-01-16
- Last Posted Date
- 2011-12-13
- Lead Sponsor
- Bausch & Lomb Incorporated
- Target Recruit Count
- 105
- Registration Number
- NCT00824070
- Locations
- 🇺🇸
Ophthalmic Consultants of Long Island, Rockville Center, New York, United States
Clinical and Microbial Efficacy of ISV403 in Bacterial Conjunctivitis
- First Posted Date
- 2008-02-25
- Last Posted Date
- 2015-03-24
- Lead Sponsor
- Bausch & Lomb Incorporated
- Target Recruit Count
- 270
- Registration Number
- NCT00622908
Systemic Pharmacokinetics of BOL-303224-A
- First Posted Date
- 2006-12-05
- Last Posted Date
- 2011-12-09
- Lead Sponsor
- Bausch & Lomb Incorporated
- Target Recruit Count
- 24
- Registration Number
- NCT00407589
- Locations
- 🇺🇸
Cornerstone Eyecare, High point, North Carolina, United States
A Study to Determine if 0.6% ISV-403 is Safe and Effective in the Treatment of Bacterial Conjunctivitis.
- First Posted Date
- 2006-07-04
- Last Posted Date
- 2015-03-24
- Lead Sponsor
- Bausch & Lomb Incorporated
- Target Recruit Count
- 957
- Registration Number
- NCT00347932
A Study to Investigate the Safety and Efficacy of BOL-303224 in the Treatment of Bacterial Conjunctivitis
- Conditions
- Acute Bacterial Conjunctivitis
- Interventions
- First Posted Date
- 2006-07-04
- Last Posted Date
- 2015-03-24
- Lead Sponsor
- Bausch & Lomb Incorporated
- Target Recruit Count
- 1161
- Registration Number
- NCT00348348
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.